Overview

A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of PF-04958242 in Healthy Subjects

Status:
Completed
Trial end date:
2015-03-31
Target enrollment:
Participant gender:
Summary
The purpose of the current study is to characterize the pharmacokinetic (PK) profile of PF 04958242 when co administered with a strong cytochrome P450 3A4 (CYP3A4) inhibitor.
Phase:
Phase 1
Details
Lead Sponsor:
Biogen
Pfizer
Treatments:
Hydroxyitraconazole
Itraconazole